Ben Markman

4.5k total citations · 2 hit papers
75 papers, 2.5k citations indexed

About

Ben Markman is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Molecular Biology. According to data from OpenAlex, Ben Markman has authored 75 papers receiving a total of 2.5k indexed citations (citations by other indexed papers that have themselves been cited), including 59 papers in Oncology, 20 papers in Pulmonary and Respiratory Medicine and 18 papers in Molecular Biology. Recurrent topics in Ben Markman's work include Cancer Immunotherapy and Biomarkers (21 papers), Colorectal Cancer Treatments and Studies (15 papers) and Lung Cancer Research Studies (15 papers). Ben Markman is often cited by papers focused on Cancer Immunotherapy and Biomarkers (21 papers), Colorectal Cancer Treatments and Studies (15 papers) and Lung Cancer Research Studies (15 papers). Ben Markman collaborates with scholars based in Australia, United States and Spain. Ben Markman's co-authors include Josep Tabernero, Rodrigo Dienstmann, José Baselga, Francesco Atzori, Maurizio Scaltriti, Joaquı́n Arribas, Elisabeth Llonch, Pieter J.A. Eichhorn, Josep Lluís Parra and Violeta Serra and has published in prestigious journals such as Nature Medicine, Journal of Clinical Oncology and Cancer Research.

In The Last Decade

Ben Markman

72 papers receiving 2.5k citations

Hit Papers

NVP-BEZ235, a Dual PI3K/mTOR Inhibitor, Prevents PI3K Sig... 2008 2026 2014 2020 2008 2024 200 400 600
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. NVP-BEZ235, a Dual PI3K/mTOR Inhibitor, Prevents PI3K Signaling and Inhibits the Growth of Cancer Cells with Activating PI3K Mutations
    2008 626 citations Violeta Serra, Ben Markman et al. Cancer Research profile →
  2. A gut microbial signature for combination immune checkpoint blockade across cancer types
    2024 67 citations Ashray Gunjur, Yan Shao et al. Nature Medicine profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Ben Markman Australia 24 1.3k 1.2k 489 334 329 75 2.5k
John Sarantopoulos United States 28 1.6k 1.2× 1.3k 1.1× 528 1.1× 257 0.8× 382 1.2× 143 3.2k
Igor Astsaturov United States 32 1.2k 0.9× 1.1k 0.9× 496 1.0× 195 0.6× 512 1.6× 97 2.7k
Ritu Roy United States 28 1.4k 1.0× 1.1k 0.9× 423 0.9× 219 0.7× 665 2.0× 64 2.9k
Jermaine Coward Australia 23 704 0.5× 1.2k 1.0× 380 0.8× 221 0.7× 354 1.1× 87 2.3k
Gregor Krings United States 27 1.2k 0.9× 825 0.7× 438 0.9× 394 1.2× 813 2.5× 62 2.8k
Christine Fritsch Switzerland 21 1.8k 1.3× 610 0.5× 401 0.8× 327 1.0× 258 0.8× 39 2.6k
Lawrence N. Kwong United States 27 1.5k 1.1× 1.2k 1.0× 397 0.8× 369 1.1× 641 1.9× 62 2.6k
Luigi Formisano Italy 25 1.1k 0.9× 1.1k 0.9× 772 1.6× 159 0.5× 494 1.5× 73 2.2k
Sidong Huang Canada 22 1.9k 1.4× 1.2k 1.0× 404 0.8× 518 1.6× 621 1.9× 44 2.9k
Stephen Leong United States 23 842 0.6× 1.1k 0.9× 471 1.0× 218 0.7× 606 1.8× 73 2.3k

Countries citing papers authored by Ben Markman

Since Specialization
Citations

This map shows the geographic impact of Ben Markman's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Ben Markman with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Ben Markman more than expected).

Fields of papers citing papers by Ben Markman

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Ben Markman. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Ben Markman. The network helps show where Ben Markman may publish in the future.

Co-authorship network of co-authors of Ben Markman

This figure shows the co-authorship network connecting the top 25 collaborators of Ben Markman. A scholar is included among the top collaborators of Ben Markman based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Ben Markman. Ben Markman is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Gunjur, Ashray, Yan Shao, Oliver Klein, et al.. (2024). A gut microbial signature for combination immune checkpoint blockade across cancer types. Nature Medicine. 30(3). 797–809. 67 indexed citations breakdown →
2.
Desai, Jayesh, Peter C.C. Fong, Víctor Moreno, et al.. (2023). A Phase 1/2 study of the PD-L1 inhibitor, BGB-A333, alone and in combination with the PD-1 inhibitor, tislelizumab, in patients with advanced solid tumours. British Journal of Cancer. 128(8). 1418–1428. 10 indexed citations
3.
4.
Rottey, Sylvie, Jeffrey Clarke, Kyaw Aung, et al.. (2022). Phase I/IIa Trial of BMS-986148, an Anti-mesothelin Antibody-drug Conjugate, Alone or in Combination with Nivolumab in Patients with Advanced Solid Tumors. EUR Research Repository (Erasmus University Rotterdam). 40 indexed citations
5.
Frentzas, Sophia, et al.. (2021). Recruitment, outcomes, and toxicity trends in phase I oncology trials: Six‐year experience in a large institution. Cancer Reports. 5(2). e1465–e1465. 1 indexed citations
6.
Raghunath, Ajay, et al.. (2020). Duration of dexamethasone administration for the prevention of chemotherapy-induced nausea and vomiting – A systematic review and meta-analysis. Critical Reviews in Oncology/Hematology. 152. 103012–103012. 4 indexed citations
7.
Klein, Oliver, Damien Kee, Ben Markman, et al.. (2020). Immunotherapy of Ipilimumab and Nivolumab in Patients with Advanced Neuroendocrine Tumors: A Subgroup Analysis of the CA209-538 Clinical Trial for Rare Cancers. Clinical Cancer Research. 26(17). 4454–4459. 116 indexed citations
8.
Markman, Ben, Ben Tran, Hui Gan, et al.. (2019). A Phase 1 study of AK104, a tetrameric bispecific antibody that targets PD-1 and CTLA-4 in patients with advanced solid tumors. Journal for ImmunoTherapy of Cancer. 7. 3 indexed citations
9.
Friedländer, Michael, Tarek Meniawy, Ben Markman, et al.. (2019). Pamiparib in combination with tislelizumab in patients with advanced solid tumours: results from the dose-escalation stage of a multicentre, open-label, phase 1a/b trial. The Lancet Oncology. 20(9). 1306–1315. 89 indexed citations
10.
Carducci, Michael A., Montaser Shaheen, Ben Markman, et al.. (2018). A phase 1, first-in-human study of AMG 900, an orally administered pan-Aurora kinase inhibitor, in adult patients with advanced solid tumors. Investigational New Drugs. 36(6). 1060–1071. 33 indexed citations
11.
12.
Meniawy, Tarek, Gary Richardson, Amanda Townsend, et al.. (2017). Preliminary results from a subset of patients (pts) with advanced ovarian cancer (OC) in a dose-escalation/expansion study of BGB-A317, an anti-PD-1 monoclonal antibody (mAb). Annals of Oncology. 28. v130–v130. 2 indexed citations
13.
Markman, Ben, Paul de Souza, Elizabeth Claire Dees, et al.. (2016). A dose-escalation study of weekly intravenous CRLX301 in patients with advanced solid tumor malignancies. Annals of Oncology. 27. vi134–vi134. 1 indexed citations
14.
Jonker, Derek J., Louise Nott, Takayuki Yoshino, et al.. (2016). A randomized phase III study of napabucasin [BBI608] (NAPA) vs placebo (PBO) in patients (pts) with pretreated advanced colorectal cancer (ACRC): the CCTG/AGITG CO.23 trial. Annals of Oncology. 27. vi150–vi150. 13 indexed citations
15.
Chu, Quincy S., Ben Markman, Natasha B. Leighl, et al.. (2016). A phase 1/2 trial of a monoclonal antibody targeting fucosyl GM1 in relapsed/refractory small cell lung cancer (SCLC): Safety and preliminary efficacy. Annals of Oncology. 27. vi494–vi494. 3 indexed citations
16.
Papadopoulos, Kyriakos P., Josep Tabernero, Ben Markman, et al.. (2014). Phase I Safety, Pharmacokinetic, and Pharmacodynamic Study of SAR245409 (XL765), a Novel, Orally Administered PI3K/mTOR Inhibitor in Patients with Advanced Solid Tumors. Clinical Cancer Research. 20(9). 2445–2456. 87 indexed citations
17.
Markman, Ben & Josep Tabernero. (2010). Monoclonal Antibodies in Solid Tumours. Current Clinical Pharmacology. 5(3). 160–165. 3 indexed citations
18.
Serrano, César, Ben Markman, & Josep Tabernero. (2010). Integration of Anti-Epidermal Growth Factor Receptor Therapies With Cytotoxic Chemotherapy. The Cancer Journal. 16(3). 226–234. 4 indexed citations
19.
Markman, Ben, et al.. (2009). Status of PI3K inhibition and biomarker development in cancer therapeutics. Annals of Oncology. 21(4). 683–691. 127 indexed citations
20.
Serra, Violeta, Ben Markman, Maurizio Scaltriti, et al.. (2008). NVP-BEZ235, a Dual PI3K/mTOR Inhibitor, Prevents PI3K Signaling and Inhibits the Growth of Cancer Cells with Activating PI3K Mutations. Cancer Research. 68(19). 8022–8030. 626 indexed citations breakdown →

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by John Sarantopoulos Breakdown of academic impact, for papers by Igor Astsaturov Breakdown of academic impact, for papers by Ritu Roy Breakdown of academic impact, for papers by Jermaine Coward Breakdown of academic impact, for papers by Gregor Krings Breakdown of academic impact, for papers by Christine Fritsch Breakdown of academic impact, for papers by Lawrence N. Kwong Breakdown of academic impact, for papers by Luigi Formisano Breakdown of academic impact, for papers by Sidong Huang Breakdown of academic impact, for papers by Stephen Leong
Rankless by CCL
2026